Results 191 to 200 of about 5,304,709 (301)

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Indication and diagnostic method selection for invasive prenatal genetic testing – review of the literature and conclusions of the Austrian consensus conference on prenatal genetic testing. [PDF]

Med Genet
Verheyen S, Pertl B, Bierbaumer S, Fazelnia C, Jauch SF, Klaritsch P, Krampl-Bettelheim E, Kühberger S, Reischer T, Reiter R, Scharnreitner I, Steiner H, Zschocke J, Pfeifer M.   +13 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Stratified Use of Genetic Testing in Liver Disease Improves Diagnostic Yield and Clinical Impact. [PDF]

Int J Mol Sci
Faini AC, Pinon M, Brach Del Prever GM, Romeo CM, Luca M, Mioli F, Saglia C, Scolari C, Carradori T, Arruga F, Chiadò C, Morgando A, Martini S, Romagnoli R, Bugianesi E, Carli D, Vaisitti T, Deaglio S, Calvo PL.   +18 more
europepmc   +1 more source

Genetic Testing and Insurance

Journal of the Royal College of Physicians of London, 1992
openaire   +2 more sources

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer. [PDF]

Hum Genet
Vlaming M, Kiemeney LALM, Koole W, van Oort IM, Bleiker EMA, Ausems MGEM, Frederix GWJ.   +6 more
europepmc   +1 more source

Law and genetic testing [PDF]

Nature, 1986
openaire   +2 more sources

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Genetic Testing Uptake Among Patients With Newly Diagnosed Breast Cancer.

JAMA Netw Open
Totten SP, Rezoug Z, Atayan A, Foulkes WD, Wong SM.   +4 more
europepmc   +1 more source